Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SRNE |
---|---|---|
09:32 ET | 405 | 0.0122 |
10:21 ET | 2327 | 0.01 |
10:42 ET | 500 | 0.015 |
10:48 ET | 600 | 0.01 |
10:55 ET | 500 | 0.01 |
10:57 ET | 200 | 0.01 |
11:13 ET | 3000 | 0.015 |
11:42 ET | 300 | 0.01 |
11:45 ET | 138 | 0.01 |
11:47 ET | 2866 | 0.015 |
11:51 ET | 700 | 0.0122 |
12:14 ET | 777 | 0.0122 |
12:20 ET | 650 | 0.01 |
12:23 ET | 200 | 0.01 |
12:54 ET | 700 | 0.01 |
12:56 ET | 176 | 0.01 |
01:46 ET | 1000 | 0.0122 |
01:48 ET | 2000 | 0.01 |
01:51 ET | 1000 | 0.0122 |
02:42 ET | 9170 | 0.01 |
03:23 ET | 265 | 0.01 |
03:25 ET | 750 | 0.01 |
03:30 ET | 1200 | 0.0122 |
03:34 ET | 1500 | 0.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sorrento Therapeutics Inc | 6.1M | 0.0x | --- |
Molecular Templates Inc | 8.4M | -0.3x | --- |
Centogene NV | 10.1M | -0.3x | --- |
Cidara Therapeutics Inc | 56.3M | -1.6x | --- |
Bioqual Inc | 64.8M | 67.8x | -25.28% |
Neptune Wellness Solutions Inc | 81.6K | 0.0x | --- |
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1M |
---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.87 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.